 Intradermal hepatitis vaccination availability vaccine immunization hepatitis virus HBV minimal impact disease mass immunization Intradermal vaccination precedent prophylaxis infectious diseases low-cost alternative traditional intramuscular HBV vaccination Results open comparative trials similar seroconversion rates intradermal intramuscular HBV vaccination routes healthy adults antibody titers duration antibody protection intradermal HBV vaccination data suggest demographic factors age gender vaccine responsiveness HBV vaccine Adverse skin reactions common deterrent intradermal HBV vaccination need large-scale prospective comparative trials value intradermal HBV vaccination Nevertheless potential economic epidemiologic benefit intradermal vaccination justifies investigation prevention HBV infection